Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05428007
Title Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health


mucosal melanoma


Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.